SCHEMBL4697615

SCHEMBL4697615

O=c1[nH]cnc2c1cnn2-c1ccc(Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.53
ALDH1A1 P00352 1/20 0.53
PDE5A O76074 7/20 0.50
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.46
CHEK1 O14757 1/20 0.45
PIM1 P11309 1/20 0.45
AKT1 P31749 1/20 0.45
FLT3 P36888 1/20 0.45
PIM3 Q86V86 1/20 0.45
GRM1 Q13255 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
GLA P06280 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17869787 0.85 HTT (0.53) HTTALDH1A1MAPTLMNAMEN1
SCHEMBL17869860 0.85 HTT (0.67) HTTALDH1A1MAPTLMNAMEN1
SCHEMBL2077064 0.85 MAPT (0.59) HTTALDH1A1PDE5AMAPTLMNA
SCHEMBL17868883 0.85 HTT (0.50) HTTALDH1A1PDE5AMAPTLMNA
SCHEMBL32668606 0.84 MAPT (0.56) HTTALDH1A1PDE5AMAPTLMNA
SCHEMBL30155205 0.84 HTT (0.54) HTTALDH1A1MAPTLMNAMEN1
SCHEMBL17869789 0.83 HTT (0.51) HTTALDH1A1MAPTLMNAMEN1
SCHEMBL17869553 0.82 XDH (0.62) HTTALDH1A1PDE5AMAPTLMNA
SCHEMBL17869621 0.82 XDH (0.60) HTTALDH1A1MAPTLMNAMEN1
SCHEMBL17869828 0.82 HTT (0.50) HTTALDH1A1MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 EP disclosed
EP-3623372-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Forma Therapeutics, Inc. (US) 2020-03-18 EP disclosed
EP-3240791-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS FORMA THERAPEUTICS INC (US) 2019-11-06 EP disclosed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP disclosed
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US disclosed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors MAP3K1, MAP4K2, MAP4K5 HTT 3429/4885ALDH1A1 1276/4885PDE5A 674/4885
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 HTT 4802/4885ALDH1A1 1978/4885PDE5A 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.